ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Valeant To Buy Branded Generics Assets From Gerot Lannach

DOW JONES NEWSWIRES Valeant Pharmaceuticals International Inc. (VRX) said Tuesday it's acquiring from Austria's Gerot Lannach certain branded generics assets that generate the bulk of their sales in Russia. Mississauga, Ont.-based Valeant said the assets generated net revenue of about $55 million last year. Gerot Lannach's largest product is acetylsalicylic acid, a low-dose aspirin. Valeant said it will pay less than three times sales, and may make up to an additional $20 million in milestone payments, based upon future performance objectives. As part of the transaction, Valeant and Gerot Lannach will enter into a strategic partnership that includes an exclusive 10-year supply agreement for the acquired products and the opportunity for Valeant to introduce additional Gerot Lannach products into Valeant territories such as its emerging markets in Southeast Asia and Latin America. Valeant expects the transaction to boost results starting immediately. -By Carolyn King, Dow Jones Newswires; 416-306-2100; carolyn.m.king@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
05/26/201607:00:00Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President...
05/26/201607:00:00Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President...
05/25/201613:00:00Pharming Reports on Annual General Meeting of Shareholders Pharming's...
05/24/201618:28:00SEC Reviewed Valeant's Use of 'Non-GAAP' Financial Measures...
05/24/201617:09:13Additional Proxy Soliciting Materials (definitive) (defa14a)
05/24/201614:30:00SEC Reviewing Valeant's Use of 'Non-GAAP' Financial Measures
05/24/201614:22:00SEC Reviewing Valeant's Use of 'Non-GAAP' Financial Measures
05/23/201607:00:00Bausch + Lomb Wins Walmart "Supplier of the Year" Award
05/23/201607:00:00Bausch + Lomb Wins Walmart "Supplier of the Year" Award
05/20/201618:20:00Valeant Investor Sequoia Fund to Limit Stakes in a Single Stock
05/20/201616:20:26Current Report Filing (8-k)
05/20/201606:07:08Current Report Filing (8-k)
05/19/201618:00:00Valeant Pharmaceuticals Receives Notice Of Default From Bondholders
05/19/201618:00:00Valeant Pharmaceuticals Receives Notice Of Default From Bondholders
05/18/201615:15:00Valeant Pharmaceuticals To Participate At The UBS Global Healthcare...
05/18/201615:15:00Valeant Pharmaceuticals To Participate At The UBS Global Healthcare...
05/18/201601:00:00Pharming Group: Interim Report on Financial Results for Q1 2016
05/16/201623:20:00Perrigo Updates First-Quarter Loss Figure to Reflect Lower Tax...
05/16/201619:00:00Valeant Pharmaceuticals Provides Update Regarding Regulatory...
05/16/201619:00:00Valeant Pharmaceuticals Provides Update Regarding Regulatory...

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad